Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Current Investments (2019 - 2025)

aTYR PHARMA's Cash & Current Investments history spans 7 years, with the latest figure at $78.7 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 9.1% year-over-year to $78.7 million; the TTM value through Dec 2025 reached $78.7 million, up 9.1%, while the annual FY2025 figure was $78.7 million, 9.1% up from the prior year.
  • Cash & Current Investments reached $78.7 million in Q4 2025 per ATYR's latest filing, down from $90.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $116.4 million in Q3 2021 to a low of $44.1 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $85.0 million, with a median of $82.4 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 240.53% in 2021, then tumbled 38.7% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $107.9 million in 2021, then crashed by 38.7% to $66.1 million in 2022, then soared by 48.41% to $98.2 million in 2023, then decreased by 26.53% to $72.1 million in 2024, then grew by 9.1% to $78.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Cash & Current Investments are $78.7 million (Q4 2025), $90.2 million (Q3 2025), and $80.3 million (Q2 2025).